Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (2022 - 2025)

Historic Shares Outstanding for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $55.1 million.

  • Stoke Therapeutics' Shares Outstanding rose 411.55% to $55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.1 million, marking a year-over-year increase of 411.55%. This contributed to the annual value of $54.0 million for FY2024, which is 1767.18% up from last year.
  • Per Stoke Therapeutics' latest filing, its Shares Outstanding stood at $55.1 million for Q3 2025, which was up 411.55% from $54.7 million recorded in Q2 2025.
  • Stoke Therapeutics' Shares Outstanding's 5-year high stood at $55.1 million during Q3 2025, with a 5-year trough of $39.0 million in Q1 2022.
  • Over the past 4 years, Stoke Therapeutics' median Shares Outstanding value was $45.9 million (recorded in 2023), while the average stood at $47.1 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Shares Outstanding surged by 1952.47% in 2024, and later skyrocketed by 411.55% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Shares Outstanding stood at $39.4 million in 2022, then grew by 16.43% to $45.9 million in 2023, then grew by 17.67% to $54.0 million in 2024, then grew by 2.01% to $55.1 million in 2025.
  • Its Shares Outstanding was $55.1 million in Q3 2025, compared to $54.7 million in Q2 2025 and $54.6 million in Q1 2025.